- Home
- VXRT
VXRT
Vaxart Inc
as 07-11-2025 2:36pm EST
VAXART INC
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 6.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.26 - $1.07 | Next Earning Date: | 08-07-2025 |
| Revenue: | $47,395,000 | Revenue Growth: | 433.43% |
| Revenue Growth (this year): | -44.74% | Revenue Growth (next year): | -75.24% |
Latest Vaxart Inc News
VXRT Breaking Stock News: Dive into VXRT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
GuruFocus.com
a month ago
Vaxart Jumps 38% After Positive Norovirus Trial
MT Newswires
a month ago
Vaxart's Oral Norovirus Vaccine Pills Meet Primary Immunological Endpoint in Phase 1 Trial
MT Newswires
a month ago
Sector Update: Health Care Stocks Higher Pre-Bell Wednesday
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Top Premarket Gainers
GlobeNewswire
a month ago
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
GlobeNewswire
a month ago
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Compare VXRT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VXRT Vaxart Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.